Biomarker Driven Drug Development

Sexually transmitted infections (STIs) continue to affect most sexually active populations across the globe, especially the traditional high-risk groups for bacterial STIs such as young people, men who have sex with men (MSM) and individuals from black and minority ethnic populations. Bacterial STIs such as Gonorrhoea and Chlamydia remain common. In western settings, we have observed the re-emergence of high rates of syphilis and lymphogranuloma venereum, mostly in MSM. Urethral and vaginal discharge syndromes, genital ulcer disease are frequent clinical presentations. However, the development of highly sensitive molecular assays has revealed that asymptomatic infections are also common, particularly at extragenital sites, and probably drive transmission of STIs.

Advanced therapy clinical trials are growing, with a record number of therapies being approved in 2021. This increase in approvals has led many to predict that the commercialization of advanced therapies is not far away .

Our 6th Annual Cancer Research & Oncology Virtual Event is now available On Demand! This free online event will bring research professionals, scientists, and clinicians from around the world to learn and discuss recent advances in cancer research. As with all LabRoots events, the Cancer Research and Oncology Event encourages a worldwide collaboration and connections between colleagues and field experts.

The boom of virtual and augmented reality in the healthcare and pharmaceutical industries is a major growth area for XR. However, there are still many regulatory challenges to overcome, and there are plenty of questions still to be answered.